Hepatic Porphyria

• CLINICAL_TRIALS research · 2026-02-17
  Clinical Trial Update: ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

  The ELEVATE registry, sponsored by Alnylam Pharmaceuticals, targets patients with Acute hepatic porphyria and is currently recruiting.

• CLINICAL_TRIALS trial_result · 2026-01-28
  Clinical Trial Update: Prevalence of Acute Hepatic Porphyria

  A completed clinical trials entry reports on the prevalence of acute hepatic porphyria.

• CLINICAL_TRIALS research · 2026-01-23
  Clinical Trial Update: Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome

  A Vanderbilt University Medical Center–led observational study aims to determine how common Acute hepatic porphyria is among people with Pos…

• CLINICAL_TRIALS approval · 2024-05-20
  Clinical Trial Update: Expanded Access Protocol of Givosiran for Patients With Acute Hepatic Porphyria

  The document indicates that the expanded access protocol for givosiran in acute hepatic porphyria has been approved for marketing.

• FDA approval · 2024-04-29
  FDA Approved: GIVLAARI — Supplemental Application (Alnylam Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for GIVLAARI (givosiran) filed by Alnylam Pharmaceuticals, updating the drug's labeling/indicati…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2023-02-10
  FDA Approved: GIVLAARI — Supplemental Application (Alnylam Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for GIVLAARI (givosiran) from Alnylam Pharmaceuticals.

• FDA approval · 2021-10-28
  FDA Approved: GIVLAARI — Supplemental Application (Alnylam Pharmaceuticals, Inc.)

  The FDA has approved a supplemental application for GIVLAARI (givosiran) by Alnylam Pharmaceuticals.

• EMA approval · 2020-01-31
  First treatment for acute hepatic porphyria

  The EMA announces the first treatment for acute hepatic porphyria, signaling a new approved therapy for this condition.

• FDA approval · 2019-11-20
  FDA Approved: GIVLAARI — Original Application (Alnylam Pharmaceuticals, Inc.)

  The FDA approved GIVLAARI (givosiran) in an Original Application for the treatment of acute hepatic porphyria, marking the drug's initial ap…